We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Eye Care

Journal Scan / Research · February 21, 2021

Safety and Efficacy of BRIMO DDS in Patients With Geographic Atrophy Secondary to AMD

Retina (Philadelphia, Pa.)


Additional Info

Retina (Philadelphia, Pa.)
Phase 2 Study of the Safety and Efficacy of Brimonidine Drug Delivery System (BRIMO DDS) Generation 1 in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Retina (Philadelphia, Pa.) 2021 Jan 01;41(1)144-155, BD Kuppermann, SS Patel, DS Boyer, AJ Augustin, WR Freeman, KJ Kerr, Q Guo, S Schneider, FJ López

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading